Will GlaxoSmithKline plc Split Itself In Two?

GlaxoSmithKline plc (LON: GSK) is weighing up a split.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) management is working hard to overhaul the FTSE 100’s largest listed pharmaceutical company, after a wave of bad news last year.   

In management’s latest attempt to create shareholder value, Glaxo’s chief executive has revealed that he is considering breaking the group up.  

Creating valuegsk

These comments from Glaxo’s management come after the pharmaceutical company unveiled a disastrous set of second-quarter results last week.

Specifically, the group reported that second quarter core operating profit plummeted 25%, or 14% on a constant exchange rate basis. Turnover fell 13%, or 4% at constant exchange rates, while core earnings per share fell 25% to 19.1p.

Unfortunately, these poor results have only compounded Glaxo’s troubles as the company tries to navigate bribery allegations. What’s more, the company is facing allegations of malpractice by employees all over the world.

Nevertheless, Glaxo’s management believes that one of the group’s most valuable assets is its consumer healthcare business. However, while Glaxo as a group is facing a storm of international criticism, investors are placing a low valuation on the company as a whole, disregarding the strengths of the consumer business.

As a result, Glaxo’s management has stated that in the future, the consumer healthcare business could be spun off, if a time came when it offered more value as a standalone company.

World leader

Thanks to its $20bn deal with Novartis earlier this year, Glaxo is set to become one of the world’s leading consumer healthcare players. Part of the deal was the creation of a consumer healthcare joint venture, with annual sales of $10bn.

Glaxo will own around 64% of the joint venture, with an option to buy out the remainder after three years.

This is where Glaxo’s management believes that value can be unlocked for shareholders. However, for the time being the consumer business fits well into the group. A spin-off right now would lead to higher costs and lower margins.

Still, the prospect of a spin-off is encouraging, especially if it creates value for shareholders.

Cash return

Glaxo’s deal with Novartis did more than create a consumer health giant. As part of the deal, Glaxo is set to receive a cash payout of £4bn, which management has promised to return to investors next year. The cash return will come as a one-off payout via a B share scheme of approximately 80p per share.

For investors, this is great news. Indeed, the one-off payout, combined with Glaxo’s current yield of 5.3%, implies that investors are in line to receive a yield of around 10% next year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »